MeSH term
Frequency | Condition_Probility | Animals | 232 | 0.0 |
Female | 113 | 0.0 |
Gene Therapy/*methods | 2 | 0.0 |
Humans | 478 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Luciferases/genetics | 2 | 0.0 |
Mice | 90 | 0.0 |
Mice, Nude | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 328 | 0.0 |
Transfection/*methods | 4 | 6.0 |
Tumor Cells, Cultured | 87 | 0.0 |
beta-Galactosidase/genetics | 3 | 2.0 |
Adult | 52 | 0.0 |
Antioxidants/*metabolism | 7 | 7.0 |
Catalase/metabolism | 4 | 6.0 |
Glutathione Peroxidase/metabolism | 2 | 5.0 |
Male | 93 | 0.0 |
Middle Aged | 47 | 0.0 |
Oxidation-Reduction | 8 | 0.0 |
Superoxide Dismutase/metabolism | 4 | 4.0 |
Aged | 48 | 0.0 |
Catalase/blood | 9 | 42.0 |
Glutathione Peroxidase/blood | 7 | 19.0 |
*Oxidative Stress | 5 | 2.0 |
Reactive Oxygen Species | 2 | 1.0 |
Superoxide Dismutase/blood | 9 | 21.0 |
Acute Disease | 2 | 0.0 |
English Abstract | 21 | 0.0 |
Gene Expression/*drug effects | 8 | 3.0 |
NF-kappa B/*metabolism | 9 | 1.0 |
Signal Transduction | 10 | 0.0 |
Transcription Factor AP-1/*metabolism | 3 | 1.0 |
Adolescent | 10 | 0.0 |
Case-Control Studies | 6 | 0.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 18 | 15.0 |
*DNA Methylation | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Promoter Regions (Genetics)/*genetics | 20 | 2.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 189 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Transcription, Genetic | 62 | 1.0 |
Binding Sites | 35 | 0.0 |
Cell Line | 98 | 0.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Blotting, Western | 14 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Cell Line, Tumor | 3 | 0.0 |
Cell Nucleus/metabolism | 15 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 23 | 3.0 |
Plasmids/genetics | 8 | 1.0 |
Transfection | 139 | 1.0 |
Catalase/*metabolism | 2 | 20.0 |
Infant, Newborn | 4 | 0.0 |
Pregnancy | 10 | 0.0 |
Risk Factors | 3 | 0.0 |
Biological Markers | 2 | 0.0 |
Catalase/*genetics | 4 | 36.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Exons | 13 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Genes, Reporter | 36 | 1.0 |
Mutagenesis, Site-Directed | 11 | 0.0 |
*Promoter Regions (Genetics) | 72 | 3.0 |
Protein Isoforms | 3 | 0.0 |
Rats | 84 | 0.0 |
Rats, Sprague-Dawley | 9 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cell Division/drug effects | 12 | 0.0 |
Clone Cells | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 8 | 0.0 |
RNA, Messenger/analysis | 14 | 0.0 |
Retinoid X Receptors | 4 | 1.0 |
Trans-Activation (Genetics)/drug effects | 4 | 1.0 |
Transcription Factor AP-1/metabolism | 4 | 1.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Tretinoin/*pharmacology | 4 | 1.0 |
Child, Preschool | 9 | 0.0 |
Infant | 5 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Hela Cells | 54 | 0.0 |
Immunoblotting | 4 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
RNA/metabolism | 2 | 0.0 |
RNA, Messenger/metabolism | 11 | 0.0 |
Time Factors | 21 | 0.0 |
*Ultraviolet Rays | 2 | 0.0 |
Dose-Response Relationship, Drug | 15 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Models, Biological | 4 | 0.0 |
Oxidative Stress | 6 | 1.0 |
Promoter Regions (Genetics) | 87 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 29 | 0.0 |
Blotting, Northern | 17 | 0.0 |
Drug Synergism | 8 | 0.0 |
Glucocorticoids/*pharmacology | 3 | 1.0 |
HIV-1/*physiology | 3 | 0.0 |
Interleukin-6/*pharmacology | 4 | 1.0 |
Receptors, Glucocorticoid/metabolism | 2 | 3.0 |
Virus Replication/drug effects | 2 | 0.0 |
Base Sequence | 176 | 0.0 |
Cells, Cultured | 68 | 0.0 |
Comparative Study | 58 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Molecular Sequence Data | 167 | 0.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 20 | 0.0 |
Trans-Activation (Genetics) | 18 | 1.0 |
Transcription Factors/genetics | 3 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Epithelial Cells/physiology | 2 | 2.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Response Elements/genetics | 3 | 1.0 |
Animals, Genetically Modified | 2 | 0.0 |
Catalase/genetics/*metabolism | 2 | 66.0 |
Superoxide Dismutase/genetics/*metabolism | 2 | 4.0 |
Apoptosis | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 80 | 28.0 |
Gene Expression | 23 | 0.0 |
Liposomes | 4 | 1.0 |
Plasmids | 44 | 3.0 |
Drug Resistance, Neoplasm/genetics | 2 | 2.0 |
Gene Deletion | 10 | 0.0 |
*Gene Expression Regulation, Enzymologic | 8 | 1.0 |
Indoles/pharmacology | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 25 | 1.0 |
*Alternative Splicing | 3 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Choline O-Acetyltransferase/analysis | 3 | 6.0 |
Nerve Tissue Proteins/analysis | 2 | 2.0 |
Haplotypes | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Child | 13 | 0.0 |
Choline O-Acetyltransferase/*metabolism | 18 | 16.0 |
Cats | 9 | 2.0 |
Culture Media/chemistry | 2 | 5.0 |
Dogs | 4 | 0.0 |
Rabbits | 10 | 0.0 |
Amino Acid Transport Systems, Basic | 4 | 36.0 |
Arginine/*metabolism | 2 | 4.0 |
Enzyme Induction | 9 | 1.0 |
Liver/enzymology | 2 | 0.0 |
RNA, Messenger/genetics | 14 | 0.0 |
Umbilical Veins | 3 | 0.0 |
Electrophoresis | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Cyclic S-Oxides/*chemistry | 2 | 100.0 |
Kinetics | 37 | 0.0 |
Protein Binding | 14 | 0.0 |
Temperature | 3 | 0.0 |
Dexamethasone/*pharmacology | 6 | 2.0 |
Estradiol/*pharmacology | 5 | 2.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Amino Acid Sequence | 45 | 0.0 |
Gene Fusion | 2 | 2.0 |
Gene Library | 4 | 0.0 |
Sequence Homology | 2 | 0.0 |
Solubility | 3 | 0.0 |
Cloning, Molecular | 52 | 0.0 |
DNA-Binding Proteins/*metabolism | 8 | 0.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
Myocardium/*metabolism | 5 | 2.0 |
Promoter Regions (Genetics)/genetics | 9 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Transcription Factors/*metabolism | 6 | 0.0 |
Transcription, Genetic/drug effects | 14 | 2.0 |
Dextran Sulfate/*pharmacology | 2 | 25.0 |
Gene Expression Regulation/drug effects | 9 | 1.0 |
HIV-1/genetics | 2 | 3.0 |
Promoter Regions (Genetics)/*drug effects | 4 | 8.0 |
Catalase/*blood | 2 | 22.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 16 | 10.0 |
DNA Damage | 3 | 0.0 |
COS Cells | 4 | 0.0 |
Cercopithecus aethiops | 7 | 0.0 |
Enhancer Elements (Genetics) | 14 | 3.0 |
*Genes, Reporter | 5 | 11.0 |
Genetic Vectors | 12 | 0.0 |
Jurkat Cells | 3 | 0.0 |
T-Lymphocytes | 2 | 0.0 |
*Trans-Activation (Genetics) | 10 | 1.0 |
Models, Molecular | 5 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
Cervix Neoplasms | 2 | 8.0 |
DNA-Binding Proteins/*genetics/metabolism | 3 | 0.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Mutation | 12 | 0.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
DNA Primers/genetics | 7 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Alleles | 3 | 0.0 |
Cathepsin D/*genetics | 2 | 12.0 |
Interleukin-6/*genetics | 2 | 2.0 |
3T3 Cells | 8 | 0.0 |
Adenoviridae/genetics | 2 | 0.0 |
Cell Division | 3 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Cell Differentiation | 5 | 0.0 |
*Gene Expression | 9 | 0.0 |
*Genes, p53 | 4 | 0.0 |
Mice, Transgenic | 21 | 0.0 |
RNA, Messenger/analysis/genetics | 5 | 1.0 |
Age Factors | 3 | 0.0 |
*Gene Expression Regulation | 34 | 1.0 |
Membrane Glycoproteins/*genetics/metabolism | 2 | 2.0 |
*Carrier Proteins | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Mutagenesis | 7 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
Heat | 4 | 0.0 |
Heat-Shock Proteins 70/*genetics | 2 | 4.0 |
Catalytic Domain | 2 | 0.0 |
Cyclic AMP/*metabolism | 4 | 1.0 |
DNA-Binding Proteins/*physiology | 7 | 1.0 |
Liver/*metabolism | 2 | 0.0 |
*Nuclear Proteins | 7 | 0.0 |
Swine | 4 | 0.0 |
Transcription Factors/*physiology | 6 | 1.0 |
*Transcription, Genetic | 29 | 1.0 |
Lipid Peroxidation | 2 | 1.0 |
Binding Sites/genetics | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis/genetics | 7 | 22.0 |
DNA/genetics | 10 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Enzyme Induction/drug effects | 5 | 1.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 22 | 13.0 |
DNA, Viral/analysis | 3 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
HIV Long Terminal Repeat/*genetics | 4 | 5.0 |
Sensitivity and Specificity | 5 | 0.0 |
Administration, Inhalation | 2 | 1.0 |
Administration, Topical | 2 | 1.0 |
Antioxidants | 2 | 6.0 |
Reproducibility of Results | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 12 | 0.0 |
Gene Expression Regulation | 21 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 3 | 0.0 |
U937 Cells | 4 | 0.0 |
Genes, Reporter/genetics | 4 | 1.0 |
Peroxidase/*genetics | 2 | 3.0 |
Enhancer Elements (Genetics)/*genetics | 2 | 2.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mutation/genetics | 3 | 0.0 |
Organ Specificity | 15 | 1.0 |
Sequence Deletion | 12 | 0.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Muscle, Skeletal/enzymology | 2 | 4.0 |
Leukemia, Erythroblastic, Acute/metabolism | 2 | 11.0 |
Platelet Aggregation Inhibitors/*pharmacology | 2 | 3.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*genetics | 2 | 25.0 |
Pyridoxal/pharmacology | 2 | 100.0 |
Pyridoxal Phosphate/pharmacology | 2 | 33.0 |
Pyridoxine/*pharmacology | 2 | 28.0 |
Cell Extracts | 2 | 1.0 |
Cholecalciferol/*metabolism | 2 | 16.0 |
DNA Footprinting | 8 | 2.0 |
Dimerization | 2 | 0.0 |
Oligonucleotides/metabolism | 5 | 6.0 |
Parathyroid Hormone/*genetics | 2 | 11.0 |
Receptors, Calcitriol/genetics/*metabolism | 2 | 6.0 |
Receptors, Retinoic Acid/genetics/metabolism | 2 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
*Response Elements | 2 | 3.0 |
Acyl-CoA Oxidase | 2 | 15.0 |
Tumor Necrosis Factor-alpha/pharmacology | 10 | 0.0 |
Gene Expression Regulation, Viral/*drug effects | 3 | 10.0 |
HIV Long Terminal Repeat/*drug effects | 3 | 37.0 |
HIV-1/*genetics | 10 | 3.0 |
Hydrocortisone/*pharmacology | 2 | 5.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
DNA Primers | 7 | 0.0 |
*Gene Expression Regulation, Viral | 10 | 3.0 |
HIV-1/genetics/*physiology | 4 | 3.0 |
Recombinant Fusion Proteins/metabolism | 6 | 0.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Malondialdehyde/blood | 3 | 4.0 |
Pedigree | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Sheep/*genetics | 2 | 3.0 |
Genetic Engineering/*methods | 2 | 13.0 |
*Genetic Vectors | 8 | 2.0 |
Lipids/*metabolism | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
CHO Cells | 5 | 0.0 |
Estradiol/pharmacology | 4 | 1.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Hamsters | 12 | 0.0 |
Ligands | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
*Transgenes | 2 | 4.0 |
Amyloid beta-Protein Precursor/*genetics | 3 | 4.0 |
Brain/*metabolism | 5 | 1.0 |
Recombinant Fusion Proteins/biosynthesis | 20 | 4.0 |
Templates, Genetic | 2 | 1.0 |
Transcription, Genetic/*drug effects | 15 | 4.0 |
Transforming Growth Factor beta/*pharmacology | 4 | 1.0 |
Introns | 11 | 0.0 |
Macaca mulatta | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 18 | 5.0 |
Electrophoresis/methods | 2 | 2.0 |
Hela Cells/metabolism | 4 | 2.0 |
Point Mutation | 6 | 0.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Fibroblasts/metabolism | 6 | 0.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Serine Endopeptidases/*metabolism | 4 | 4.0 |
*Protein Biosynthesis | 3 | 0.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Binding, Competitive | 8 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Molecular Weight | 6 | 0.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Breast Neoplasms | 4 | 1.0 |
DNA/*metabolism | 4 | 0.0 |
Liver Neoplasms | 4 | 1.0 |
Prostatic Neoplasms | 2 | 3.0 |
Prognosis | 8 | 0.0 |
Survival Rate | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Chimera | 2 | 1.0 |
Lung/immunology | 2 | 6.0 |
*Virus Replication | 2 | 0.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Trans-Activators/*physiology | 3 | 1.0 |
Cathepsin D/*analysis | 3 | 15.0 |
Survival Analysis | 3 | 0.0 |
Models, Genetic | 4 | 0.0 |
Transcription, Genetic/physiology | 2 | 1.0 |
Chick Embryo | 4 | 0.0 |
Cytomegalovirus/genetics | 4 | 4.0 |
Mice, Inbred Strains | 3 | 0.0 |
Sarcoma Viruses, Avian/genetics | 2 | 10.0 |
Simian virus 40/genetics | 9 | 8.0 |
Catechols/*pharmacology | 2 | 16.0 |
Estradiol/blood | 2 | 0.0 |
Indicators and Reagents | 3 | 1.0 |
Receptors, Estrogen/drug effects | 2 | 15.0 |
Adenosine Deaminase/*genetics | 2 | 8.0 |
DNA/metabolism | 13 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Receptors, Estrogen/*metabolism | 4 | 1.0 |
Transcription Factor, Sp1/*metabolism | 4 | 1.0 |
Brain/metabolism | 2 | 0.0 |
*Drosophila Proteins | 3 | 0.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
*Proto-Oncogenes | 3 | 0.0 |
Transcription Factors/metabolism | 9 | 0.0 |
5' Untranslated Regions | 2 | 1.0 |
Hepacivirus/*genetics | 2 | 8.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Protein Biosynthesis | 9 | 0.0 |
*Endopeptidases | 2 | 6.0 |
Neoplasm Metastasis | 3 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis/metabolism | 3 | 11.0 |
*Genes, Regulator | 8 | 7.0 |
Interleukin-10/*pharmacology | 2 | 2.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Macromolecular Substances | 7 | 0.0 |
Vero Cells | 4 | 1.0 |
Virus Replication | 6 | 0.0 |
Drug Stability | 2 | 0.0 |
*Gene Transfer Techniques | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Homeostasis | 2 | 0.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Cathepsins/*antagonists & inhibitors | 3 | 60.0 |
Leukocyte Elastase/*antagonists & inhibitors | 2 | 22.0 |
Actins/genetics | 2 | 1.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Receptors, Glucocorticoid/physiology | 2 | 14.0 |
Alzheimer Disease/*enzymology | 6 | 12.0 |
Autopsy | 3 | 1.0 |
Biological Transport, Active | 2 | 1.0 |
Brain/*enzymology | 8 | 4.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Follow-Up Studies | 2 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Transcription, Genetic/genetics | 5 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Acetylcholine/*physiology | 2 | 11.0 |
Choline O-Acetyltransferase/metabolism | 17 | 11.0 |
Histocytochemistry | 6 | 0.0 |
Neurons/*physiology | 2 | 1.0 |
Insulin/genetics | 2 | 6.0 |
Proteins/*genetics | 5 | 0.0 |
*Transcription, Genetic/drug effects | 3 | 2.0 |
Reference Values | 9 | 0.0 |
Aging | 4 | 1.0 |
Sequence Analysis | 2 | 0.0 |
Chickens | 6 | 0.0 |
Chromosome Mapping | 15 | 0.0 |
DNA, Viral | 4 | 2.0 |
Genome, Viral | 2 | 1.0 |
RNA Splicing | 3 | 0.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Carcinoma, Hepatocellular | 5 | 1.0 |
Genes, Viral | 10 | 4.0 |
Hepatitis B virus/*genetics | 3 | 10.0 |
Cell Line, Transformed | 7 | 0.0 |
Keratinocytes/enzymology | 2 | 13.0 |
Nuclear Proteins/metabolism | 11 | 1.0 |
Protein Precursors/*genetics | 4 | 3.0 |
Cyclic AMP/physiology | 2 | 1.0 |
Regulatory Sequences, Nucleic Acid | 12 | 2.0 |
Gene Expression/drug effects | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Exons/genetics | 4 | 0.0 |
Introns/genetics | 2 | 0.0 |
Restriction Mapping | 25 | 1.0 |
*Chromosome Deletion | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Heterozygote | 2 | 0.0 |
Cattle | 8 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Blotting, Southern | 11 | 0.0 |
Embryo | 3 | 0.0 |
Recombinant Fusion Proteins/genetics | 4 | 2.0 |
*Recombination, Genetic | 3 | 0.0 |
Cell Survival | 4 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/*metabolism | 3 | 100.0 |
*Transfection | 10 | 4.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Isoenzymes/*biosynthesis | 2 | 3.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
*Genes, Structural | 13 | 1.0 |
DNA, Complementary/genetics | 9 | 0.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Mucins/*genetics | 2 | 1.0 |
Trachea/metabolism | 2 | 11.0 |
Up-Regulation | 9 | 0.0 |
Recombinant Fusion Proteins | 5 | 1.0 |
*Genome, Viral | 2 | 2.0 |
Parainfluenza Virus 3, Human/*genetics | 2 | 66.0 |
Viral Core Proteins/genetics | 2 | 28.0 |
Viral Proteins/genetics | 3 | 4.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Gene Expression Regulation, Enzymologic/drug effects | 3 | 1.0 |
Vitellogenins/genetics | 3 | 50.0 |
Cathepsin B/*metabolism | 2 | 20.0 |
Isoenzymes | 2 | 1.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
DNA | 9 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Cycloheximide/pharmacology | 6 | 0.0 |
NF-kappa B/metabolism | 5 | 0.0 |
Ultraviolet Rays | 6 | 0.0 |
*DNA Damage | 4 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Proteins/*analysis | 2 | 1.0 |
Receptors, Estrogen/*analysis | 3 | 1.0 |
Receptors, Progesterone/*analysis | 2 | 0.0 |
Cytomegalovirus/*genetics/metabolism | 2 | 50.0 |
Interleukin-6/*biosynthesis/genetics | 2 | 5.0 |
Monocytes/*metabolism | 2 | 0.0 |
Viral Proteins/*genetics/metabolism | 2 | 11.0 |
Gene Expression Regulation, Viral | 6 | 2.0 |
Virus Replication/*physiology | 2 | 3.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
DNA, Recombinant | 4 | 2.0 |
Metallothionein/genetics | 2 | 5.0 |
HIV Long Terminal Repeat | 4 | 2.0 |
Oligonucleotide Probes | 6 | 0.0 |
Estrogen Antagonists/*pharmacology | 3 | 4.0 |
Transfection/genetics | 4 | 2.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
*Genes, Viral | 5 | 2.0 |
Viral Proteins/*genetics | 2 | 2.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-fos/metabolism | 2 | 1.0 |
Consensus Sequence | 6 | 0.0 |
Transforming Growth Factor alpha/*genetics | 2 | 4.0 |
Antibodies | 3 | 0.0 |
RNA, Messenger/biosynthesis/drug effects | 2 | 3.0 |
TATA Box | 6 | 1.0 |
Thymidine Kinase/genetics | 7 | 8.0 |
Chloramphenicol O-Acetyltransferase/*genetics | 4 | 57.0 |
Enkephalins/*genetics | 2 | 18.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 5 | 3.0 |
Smoke/*adverse effects | 2 | 10.0 |
Genetic Vectors/genetics | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Oligodeoxyribonucleotides | 14 | 1.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Gene Expression/*radiation effects | 2 | 16.0 |
Conserved Sequence | 5 | 0.0 |
Genes, Regulator | 4 | 3.0 |
Phylogeny | 2 | 0.0 |
Primates | 2 | 2.0 |
Protein Conformation | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 14 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Calcium Phosphates | 2 | 50.0 |
Fetus | 2 | 0.0 |
In Vitro | 17 | 0.0 |
Base Composition | 4 | 1.0 |
Tissue Distribution | 7 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
DNA Probes | 5 | 0.0 |
Methylation | 3 | 0.0 |
Fibroblasts/drug effects/metabolism | 3 | 2.0 |
*HIV Long Terminal Repeat | 4 | 4.0 |
Fibroblasts/drug effects/physiology | 2 | 10.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Adenoviruses, Human/*genetics | 2 | 1.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 3 | 4.0 |
Gene Expression Regulation, Enzymologic/*physiology | 4 | 4.0 |
Kidney | 2 | 0.0 |
DNA/genetics/metabolism | 3 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 5 | 1.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
Cell Differentiation/physiology | 2 | 0.0 |
HIV/*genetics | 4 | 6.0 |
*Enhancer Elements (Genetics) | 11 | 3.0 |
Immunoglobulins, lambda-Chain/*genetics | 2 | 12.0 |
Fibroblasts | 4 | 0.0 |
*Promoter Regions (Genetics)/drug effects | 4 | 10.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Deoxyribonuclease I | 4 | 2.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
Aspartic Acid/metabolism | 2 | 7.0 |
Neurons/*metabolism | 2 | 0.0 |
Receptors, Cholinergic/metabolism | 2 | 10.0 |
Alzheimer Disease/*physiopathology | 2 | 10.0 |
Hydrolases/metabolism | 2 | 14.0 |
Phosphoenolpyruvate Carboxykinase (GTP)/*genetics | 2 | 11.0 |
RNA/analysis | 2 | 0.0 |
Kidney/cytology | 2 | 1.0 |
Collagen/*genetics | 2 | 0.0 |
Genes, Synthetic | 5 | 9.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
*Transcription Factors | 3 | 0.0 |
DNA Mutational Analysis | 13 | 0.0 |
Genomic Library | 6 | 1.0 |
Aging/*metabolism | 2 | 0.0 |
Postmortem Changes | 3 | 4.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Spodoptera | 2 | 0.0 |
Cyclic AMP/*pharmacology | 2 | 3.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Proto-Oncogene Proteins c-raf | 2 | 1.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Genes, Structural | 7 | 0.0 |
*Genes, tat | 2 | 6.0 |
Recombination, Genetic | 3 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 5 | 1.0 |
Thymidine Kinase/biosynthesis | 2 | 40.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
HIV Long Terminal Repeat/*radiation effects | 3 | 75.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
Acetylcholine/*metabolism | 3 | 9.0 |
Thyroid Neoplasms/*genetics | 2 | 2.0 |
Trans-Activators/*genetics | 5 | 1.0 |
DNA/*genetics | 6 | 1.0 |
Polyomavirus/*genetics | 2 | 40.0 |
Endosomes/*enzymology | 2 | 28.0 |
In Situ Hybridization | 2 | 0.0 |
Lysosomes/*enzymology | 3 | 6.0 |
Nerve Degeneration | 2 | 3.0 |
Keratin/*genetics | 3 | 4.0 |
Tissue Inhibitor of Metalloproteinases | 2 | 3.0 |
Growth Hormone/genetics | 2 | 10.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Elastin/*genetics | 3 | 11.0 |
Biological Transport | 4 | 0.0 |
Viral Core Proteins/genetics/*physiology | 2 | 40.0 |
Muscles/*enzymology | 2 | 2.0 |
8-Bromo Cyclic Adenosine Monophosphate/*pharmacology | 2 | 13.0 |
Androgens/*pharmacology | 2 | 3.0 |
Ethers, Cyclic/pharmacology | 2 | 5.0 |
Forskolin/pharmacology | 4 | 1.0 |
Okadaic Acid | 3 | 6.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
Aromatase/*genetics | 2 | 8.0 |
Heat-Shock Proteins/*genetics | 2 | 2.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Monocytes/*microbiology | 2 | 7.0 |
*Genes, Dominant | 2 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Lod Score | 2 | 0.0 |
Species Specificity | 7 | 0.0 |
Catalase/genetics | 3 | 37.0 |
Cattle/*genetics | 3 | 2.0 |
Parathyroid Hormone/genetics | 2 | 12.0 |
*Chromosomes, Human, Pair 11 | 4 | 0.0 |
Metals/*pharmacology | 2 | 14.0 |
Proto-Oncogene Proteins c-jun/*metabolism | 2 | 2.0 |
DNA, Complementary | 3 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Cyclooxygenase Inhibitors/*pharmacology | 2 | 5.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Liver Neoplasms, Experimental/metabolism | 2 | 10.0 |
Mice, Inbred C3H | 2 | 0.0 |
Hominidae/*genetics | 2 | 1.0 |
Renin/biosynthesis/*genetics | 2 | 66.0 |
Simplexvirus/enzymology | 2 | 20.0 |
HIV Long Terminal Repeat/genetics | 3 | 6.0 |
Mesocricetus | 2 | 1.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Codon | 4 | 0.0 |
Metalloendopeptidases/*genetics | 2 | 2.0 |
Genes, tat | 3 | 10.0 |
Hydrolysis | 2 | 0.0 |
Cricetulus | 2 | 0.0 |
Serine Proteinase Inhibitors/*genetics | 2 | 7.0 |
*Proteins | 4 | 0.0 |
Brain Mapping | 2 | 1.0 |
*Immunoenzyme Techniques | 2 | 1.0 |
Genes, fos | 2 | 1.0 |
*Genetic Techniques | 2 | 3.0 |
Proto-Oncogene Proteins c-jun/genetics | 2 | 5.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Gene Expression Regulation/drug effects/*physiology | 2 | 2.0 |
Pregnancy Proteins/*genetics | 2 | 5.0 |
Histones/*genetics | 2 | 7.0 |
Epithelial Cells | 3 | 0.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
*Genes, myc | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Transferrin/biosynthesis/*genetics | 2 | 33.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Glucuronidase/metabolism | 2 | 6.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Platelet Aggregation/drug effects | 2 | 0.0 |
DNA Replication | 3 | 0.0 |
DNA, Viral/*genetics | 3 | 4.0 |
Simian virus 40/*genetics | 3 | 5.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Open Reading Frames | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 2 | 1.0 |
Chloramphenicol O-Acetyltransferase/*genetics/metabolism | 2 | 66.0 |
DNA, Viral/genetics | 2 | 1.0 |
HIV Long Terminal Repeat/*drug effects/genetics | 2 | 66.0 |
Karyotyping | 2 | 0.0 |
Peroxidases/blood | 2 | 18.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 2 | 6.0 |
*Genes, MHC Class I | 2 | 0.0 |
*Genes | 2 | 0.0 |
Gentamicins/pharmacology | 2 | 11.0 |
HIV-1/drug effects/*genetics | 2 | 11.0 |
Cosmids | 3 | 0.0 |
Stromelysin 1 | 2 | 5.0 |
Glycoproteins/*genetics | 3 | 1.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Cathepsins/*metabolism | 2 | 12.0 |
Receptors, Progesterone/metabolism | 3 | 1.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
Repetitive Sequences, Nucleic Acid/*drug effects/genetics | 2 | 66.0 |
Stimulation, Chemical | 3 | 0.0 |
Genome, Human | 2 | 0.0 |
Haplorhini | 3 | 1.0 |
Receptors, Calcitriol | 2 | 4.0 |
Herpesvirus 4, Human/*genetics | 3 | 4.0 |
Acquired Immunodeficiency Syndrome/drug therapy | 2 | 6.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromosome Deletion | 5 | 0.0 |
*Chimera | 3 | 9.0 |
Kanamycin Kinase | 2 | 16.0 |
Simplexvirus/*genetics | 2 | 7.0 |
Deoxyribonuclease I/metabolism | 3 | 2.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Regulatory Sequences, Nucleic Acid/*physiology | 2 | 18.0 |
Renin/*genetics | 2 | 7.0 |
L-Lactate Dehydrogenase/metabolism | 3 | 2.0 |
BK Virus/*genetics | 3 | 33.0 |
DNA/isolation & purification | 2 | 1.0 |
*Plasmids | 3 | 7.0 |
Hela Cells/enzymology | 2 | 5.0 |
Evolution | 3 | 0.0 |
*Multigene Family | 2 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Chloramphenicol O-Acetyltransferase | 15 | 37.0 |
Xenopus laevis | 2 | 0.0 |
Cytomegalovirus/*genetics | 3 | 8.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Rats, Inbred Strains | 8 | 1.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Globins/genetics | 4 | 3.0 |
Autoradiography | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Neurotransmitters/*metabolism | 3 | 10.0 |
Transcription Factors/physiology | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/analysis/genetics | 2 | 33.0 |
Protein p53 | 2 | 8.0 |
Globins/*genetics | 2 | 1.0 |
Cloning, Molecular/methods | 2 | 1.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Alzheimer Disease/*metabolism | 4 | 1.0 |
Chorionic Gonadotropin/*genetics | 2 | 33.0 |
Chorionic Gonadotropin, beta Subunit, Human | 2 | 4.0 |
Nucleoside Deaminases/*genetics | 2 | 13.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Immunosorbent Techniques | 2 | 0.0 |
Haptoglobins/*genetics | 2 | 5.0 |
Cross Reactions | 2 | 0.0 |
DNA Restriction Enzymes | 5 | 1.0 |
*Cloning, Molecular | 2 | 0.0 |
Carnitine O-Acetyltransferase/metabolism | 2 | 50.0 |
Pyruvate Dehydrogenase Complex/*metabolism | 2 | 11.0 |
Immunochemistry | 3 | 1.0 |
Glutamate Decarboxylase/*metabolism | 5 | 71.0 |
Neurons/*enzymology | 2 | 2.0 |
Acetyltransferases/genetics | 9 | 24.0 |
*Brain Chemistry | 4 | 2.0 |
DNA/analysis | 2 | 0.0 |
Alzheimer Disease/*enzymology/metabolism | 2 | 50.0 |
*Oncogenes | 2 | 0.0 |
Glutamate Decarboxylase/metabolism | 4 | 23.0 |
Dopamine/metabolism | 2 | 1.0 |
Receptors, Cholinergic/*physiology | 3 | 33.0 |
Synaptic Transmission | 2 | 5.0 |
Acetylcholinesterase/*metabolism | 5 | 3.0 |
Alzheimer Disease/enzymology | 2 | 13.0 |
Parkinson Disease/enzymology | 2 | 25.0 |
Cerebral Cortex/enzymology | 2 | 9.0 |
Brain/enzymology | 2 | 1.0 |
Acoustic Stimulation | 2 | 2.0 |
Acetyltransferases/*metabolism | 3 | 3.0 |
Carnitine O-Acetyltransferase/*metabolism | 2 | 100.0 |
Amygdala/enzymology | 2 | 33.0 |
Caudate Nucleus/enzymology | 3 | 33.0 |
Dementia/*enzymology | 2 | 20.0 |
Hippocampus/enzymology | 3 | 14.0 |
Huntington Disease/*enzymology | 3 | 42.0 |
Putamen/enzymology | 2 | 25.0 |
Carboxy-Lyases/*metabolism | 3 | 25.0 |
Scopolamine/pharmacology | 2 | 33.0 |
Acetylcholinesterase/metabolism | 2 | 2.0 |
Substantia Nigra/enzymology | 2 | 33.0 |
